On January 9, Innovent announced that GLP-1R GCGR dual agonistMaxdotide met the primary endpoint and all key secondary endpoints in the first Phase III clinical study (GLORY-1) in the case of overweight or obesity in China**.
Innovent said it plans to submit a new drug application for the indication of weight loss in the near future.
Max Tide is a product introduced by Innovent from Eli LillyAt present, the GLP-1R GCGR dual agonist with the fastest clinical development progress in the world. The GLORY-1 study enrolled a total of 610 participants in the 4 mg, 6 mg, and placebo groups for 48 weeks. Clinical results showed that**After 32 weeks, the percentage change from baseline in body weight and the proportion of subjects with a 5% decrease in body weight from baseline were significantly better than those in the placebo group. It is more effective after 48 weeks of use. All other key secondary endpoints of the study were met. Overall safety was good throughout the ** period.
On December 26, 2023, according to the drug clinical trial registration and information publicity platform, Innovent Biologics launched Max Thotide peptideA head-to-head phase III clinical trial of semaglutide in Chinese patients with early-stage type 2 diabetes mellitus and obesity.
Written by |Yang Xixia.
Edit |Jiang Yun Jia Ting.
Operations |Valley.
Illustration |Visual China.